PXS Archives - ShareCafe

Morgans initiates coverage of commercial stage drug development company Pharmaxis with a Speculative Buy rating and $0.58 target price.

Bhronchitol FDA Approval Transformative for Pharmaxis

November 2, 2020November 2, 2020 - by Company News

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced the United States Food and Drug Administration (FDA) has approved Bronchitol® (mannitol) as add‐on maintenance therapy to improve pulmonary function in cystic fibrosis (CF) patients 18 years of age and older.